Othmane Tel H et al. Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study. (2007) HEMODIALYSIS INTERNATIONAL 1492-7535 1542-4758 11 Suppl. 3 S13-S21,
1869321
Toussaint Nigel D et al. Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. (2012) NEPHROLOGY 1320-5358 1440-1797 17 5 433-444
Matsumae T et al. What factors accelerate aortic stiffening in hemodialysis patients An observational study. (2010) HYPERTENSION RESEARCH 0916-9636 1348-4214 33 3 243-249
Grinfeld J et al. Update and critical appraisal of sevelamer in the management of chronic renal failure. (2010) Open Access Journal of Urology 1179-1551 2 1 161-170
Shroff RC et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. (2008) NEPHROLOGY DIALYSIS TRANSPLANTATION 0931-0509 1460-2385 23 10 3263-3271
Sampath TK et al. Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats. (2008) ENDOCRINOLOGY 0013-7227 1945-7170 149 12 6092-6102
Marangon N et al. Nonphosphate-binding effects of sevelamer - Are they of clinical relevance?. (2008) SEMINARS IN DIALYSIS 0894-0959 1525-139X 21 5 385-389
Bellasi A et al. Arterial stiffness, pulse wave analyses: What can't blood pressure tell you in Chronic Kidney Disease. (2012) CURRENT HYPERTENSION REVIEWS 1573-4021 8 4 244-249
Kim HR et al. The ratio of osteoprotegerin to fetuin-a ii independently associated with vascular stiffness in hemodialysis patients. (2013) NEPHRON CLINICAL PRACTICE 1660-2110 123 3-4 165-172